Retina/Vitreous News

The K8 implant, a first-in-class dual inflammasome inhibitor, demonstrated positive efficacy and safety at 3 months in five patients with bilateral geographic atrophy, according to a press release from Inflammasome Therapeutics.

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.

The foveal avascular zone, or FAZ, area deteriorated at 12 months in eyes with stable laser-treated proliferative diabetic retinopathy and macular capillary nonperfusion, but vision loss was not common, according to a study.

RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s lead candidate gene therapy for optogenetic vision restoration, according to a press release.

City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA interference-based treatment for geographic atrophy, according to a press release.

NEW YORK — In this presentation from OSN New York Retina, Majda Hadziahmetovic, MD, of Duke University, discusses the growing role of Home OCT and how it offers precise personalization in retinal disease treatment.

Atsena Therapeutics initiated part B of the phase 1/2 LIGHTHOUSE study investigating ATSN-201 for the treatment of X-linked retinoschisis, according to a press release.

The FDA granted rare pediatric disease designation to VG901 for the treatment of retinitis pigmentosa caused by mutations in the CNGA1 gene, according to a press release from ViGeneron.

NEW YORK — In this presentation from OSN New York Retina, Carl D. Regillo, MD, of Wills Eye Hospital, provides guidelines for the treatment of proliferative diabetic retinopathy.